Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD19-chimeric Antigen Receptor T Cells”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableNo Longer AvailableNCT03594162
What this trial is testing

Compassionate Use of CAR T Cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch

Who this might be right for
Acute Lymphoblastic LeukemiaImmune System DiseasesImmunoproliferative Disorders
UNC Lineberger Comprehensive Cancer Center
Early research (Phase 1)Looking for participantsNCT07361029
What this trial is testing

CD19 Chimeric Antigen Receptor (CAR) T Cells in Adults With Relapsed/Refractory CD19 Positive Acute Lymphoblastic Leukemia

Who this might be right for
Relapsed Refractory Acute Lymphoblastic Leukemia
King Faisal Specialist Hospital & Research Center 24
Early research (Phase 1)Study completedNCT02976857
What this trial is testing

Study Evaluating Safety and Efficacy of C-CAR011 Treatment in DLBCL Subjects

Who this might be right for
Refractory Diffuse Large B-Cell Lymphoma
Shanghai AbelZeta Ltd. 15
Not applicableUnknownNCT03488160
What this trial is testing

CAR-T Treatment for Relapse / Refractory Type Safety and Effectiveness of Lymphoma

Who this might be right for
Lymphoma
Sinobioway Cell Therapy Co., Ltd. 6
Early research (Phase 1)UnknownNCT04037566
What this trial is testing

CRISPR (HPK1) Edited CD19-specific CAR-T Cells (XYF19 CAR-T Cells) for CD19+ Leukemia or Lymphoma.

Who this might be right for
Leukemia Lymphocytic Acute (ALL) in RelapseLeukemia Lymphocytic Acute (All) RefractoryLymphoma, B-Cell+1 more
Xijing Hospital 40
Testing effectiveness (Phase 2)UnknownNCT04714827
What this trial is testing

Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Shanxi Province Cancer Hospital 24
Early research (Phase 1)Looking for participantsNCT06593145
What this trial is testing

CAR T Cells in the Treatment of Refractory and Relapsed CD19+ B Cell Neoplasms

Who this might be right for
Acute Lymphoblastic Leukemia (ALL)Mantle Cell Lymphoma (MCL)Large B-cell Lymphoma
FamiCordTx 6
Early research (Phase 1)Looking for participantsNCT07115745
What this trial is testing

Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases

Who this might be right for
Refractory Autoimmune Diseases
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company 125
Early research (Phase 1)Active Not RecruitingNCT06152172
What this trial is testing

CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101

Who this might be right for
Idiopathic Inflammatory MyopathiesDiffuse Cutaneous Systemic SclerosisSLE Nephritis+1 more
David Porter 24
Testing effectiveness (Phase 2)Looking for participantsNCT06121297
What this trial is testing

RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

Who this might be right for
Systemic Lupus ErythematosusLupus Nephritis
Cabaletta Bio 28
Early research (Phase 1)Active Not RecruitingNCT05707273
What this trial is testing

CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First Remission

Who this might be right for
B Acute Lymphoblastic Leukemia
City of Hope Medical Center 18
Very early researchLooking for participantsNCT07246096
What this trial is testing

Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases

Who this might be right for
Autoimmune DiseasesSystemic Lupus ErythematosusSystemic Sclerosis+3 more
Changhai Hospital 60
Testing effectiveness (Phase 2)UnknownNCT05164042
What this trial is testing

Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Who this might be right for
Relapse LeukemiaRefractory Leukemia
Shenzhen University General Hospital 20
Testing effectiveness (Phase 2)Looking for participantsNCT06247501
What this trial is testing

Treatment of CD19 Chimeric Antigen Receptor T Cells for Pediatric Patients With CD19-positive B-cell Acute Lymphoblastic Leukemia Who Are Indicated for Hematopoietic Stem Cell Transplantation

Who this might be right for
Very High Risk Acute Lymphoblastic LeukemiaCD19 CAR-T Therapy
Seoul National University Hospital 50
Early research (Phase 1)UnknownNCT03154775
What this trial is testing

Study of Safety and Efficacy of C-CAR011 in B-NHL Patients

Who this might be right for
Refractory or Relapsed Non-Hodgkin Lymphoma
Shanghai AbelZeta Ltd. 15
Large-scale testing (Phase 3)Not Yet RecruitingNCT07335562
What this trial is testing

Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis

Who this might be right for
Systemic Sclerosis
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company 92
Testing effectiveness (Phase 2)UnknownNCT03366324
What this trial is testing

Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies

Who this might be right for
Acute Lymphoblastic LeukemiaB Cell Lymphoma
Wuhan Sian Medical Technology Co., Ltd 20
Testing effectiveness (Phase 2)Looking for participantsNCT04989803
What this trial is testing

Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma

Who this might be right for
Relapsed and/or Refractory B-cell Lymphoma
Kite, A Gilead Company 247
Testing effectiveness (Phase 2)Looking for participantsNCT07328503
What this trial is testing

CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Who this might be right for
Acute Lymphoblastic LeukemiaB-All
National Cancer Institute (NCI) 20
Testing effectiveness (Phase 2)UnknownNCT02772198
What this trial is testing

T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies

Who this might be right for
Acute Lymphoblastic Leukemia, B-precursorNon-Hodgkin Lymphoma, B-cell
Sheba Medical Center 300
Next Page